Role of C5b-9 and RGC-32 in Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Jun 4

PMID 31156630

Citations 13

Authors

Sonia I Vlaicu

Alexandru Tatomir

Violeta Rus

Horea Rus

Affiliations

Soon will be listed here.

Abstract

The complement system represents an effective arsenal of innate immunity as well as an interface between innate and adaptive immunity. Activation of the complement system culminates with the assembly of the C5b-9 terminal complement complex on cell membranes, inducing target cell lysis. Translation of this sequence of events into a malignant setting has traditionally afforded C5b-9 a strict antitumoral role, in synergy with antibody-dependent tumor cytolysis. However, in recent decades, a plethora of evidence has revised this view, highlighting the tumor-promoting properties of C5b-9. Sublytic C5b-9 induces cell cycle progression by activating signal transduction pathways (e.g., Gi protein/ phosphatidylinositol 3-kinase (PI3K)/Akt kinase and Ras/Raf1/ERK1) and modulating the activation of cancer-related transcription factors, while shielding malignant cells from apoptosis. C5b-9 also induces Response Gene to Complement (RGC)-32, a gene that contributes to cell cycle regulation by activating the Akt and CDC2 kinases. RGC-32 is expressed by tumor cells and plays a dual role in cancer, functioning as either a tumor promoter by endorsing malignancy initiation, progression, invasion, metastasis, and angiogenesis, or as a tumor suppressor. In this review, we present recent data describing the versatile, multifaceted roles of C5b-9 and its effector, RGC-32, in cancer.

Citing Articles

The role of complement in tumor immune tolerance and drug resistance: a double-edged sword.

Yang R, Fu D, Liao A Front Immunol. 2025; 16:1529184.

PMID: 39958348 PMC: 11825488. DOI: 10.3389/fimmu.2025.1529184.

New insights into the role of complement system in colorectal cancer (Review).

Xu Y, Zhou J, Wu Y, Shen J, Fu X, Liu M Mol Med Rep. 2025; 31(3.

PMID: 39791217 PMC: 11751662. DOI: 10.3892/mmr.2025.13433.

Analysis of immune cell activation in patients with diabetes foot ulcer from the perspective of single cell.

Vu L, Xu F, Li T, Hua Q, Kuang X, Jiang Y Eur J Med Res. 2024; 29(1):606.

PMID: 39702546 PMC: 11657181. DOI: 10.1186/s40001-024-02179-7.

Metformin Inhibits the Progression of Pancreatic Cancer Through Regulating miR-378a-3p/VEGFA/RGC-32 Axis.

He J, Luo Y, Ding Y, Zhu L Cancer Med. 2024; 13(23):e70446.

PMID: 39606802 PMC: 11602749. DOI: 10.1002/cam4.70446.

Downregulation of complement factor H attenuates the stemness of MDA‑MB‑231 breast cancer cells via modulation of the ERK and p38 signaling pathways.

Park S, Eum D, Jin Y, Lee C, Shim J, Choi S Oncol Lett. 2023; 26(6):521.

PMID: 37927420 PMC: 10623083. DOI: 10.3892/ol.2023.14107.

References

Niculescu F, Soane L, Badea T, Shin M, Rus H . Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. Immunopharmacology. 1999; 42(1-3):187-93. DOI: 10.1016/s0162-3109(99)00014-4. View

Cybulsky A, Takano T, Papillon J, McTavish A . Complement C5b-9 induces receptor tyrosine kinase transactivation in glomerular epithelial cells. Am J Pathol. 1999; 155(5):1701-11. PMC: 1866958. DOI: 10.1016/S0002-9440(10)65485-5. View

Soane L, Rus H, Niculescu F, Shin M . Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J Immunol. 1999; 163(11):6132-8. View

Cragg M, Howatt W, Bloodworth L, Anderson V, Morgan B, Glennie M . Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ. 2000; 7(1):48-58. DOI: 10.1038/sj.cdd.4400627. View

Viedt C, Hansch G, Brandes R, Kubler W, Kreuzer J . The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1. FASEB J. 2000; 14(15):2370-2. DOI: 10.1096/fj.00-0468fje. View

Rus H, Niculescu F, Shin M . Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev. 2001; 180:49-55. DOI: 10.1034/j.1600-065x.2001.1800104.x. View

Soane L, Cho H, Niculescu F, Rus H, Shin M . C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J Immunol. 2001; 167(4):2305-11. DOI: 10.4049/jimmunol.167.4.2305. View

Niculescu F, Rus H . Mechanisms of signal transduction activated by sublytic assembly of terminal complement complexes on nucleated cells. Immunol Res. 2001; 24(2):191-9. DOI: 10.1385/ir:24:2:191. View

Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H, Rus V . RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem. 2001; 277(1):502-8. DOI: 10.1074/jbc.M109354200. View

10.

Inoue T, Yamakawa M, Takahashi T . Expression of complement regulating factors in gastric cancer cells. Mol Pathol. 2002; 55(3):193-9. PMC: 1187173. DOI: 10.1136/mp.55.3.193. View

11.

Donin N, Jurianz K, Ziporen L, Schultz S, Kirschfink M, Fishelson Z . Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin Exp Immunol. 2003; 131(2):254-63. PMC: 1808622. DOI: 10.1046/j.1365-2249.2003.02066.x. View

12.

Zwaka T, Torzewski J, Hoeflich A, Dejosez M, Kaiser S, Hombach V . The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop. FASEB J. 2003; 17(10):1346-8. DOI: 10.1096/fj.02-0814fje. View

13.

Kang Y, Siegel P, Shu W, Drobnjak M, Kakonen S, Cordon-Cardo C . A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003; 3(6):537-49. DOI: 10.1016/s1535-6108(03)00132-6. View

14.

Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M . Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol. 2003; 40(2-4):109-23. DOI: 10.1016/s0161-5890(03)00112-3. View

15.

Niculescu F, Rus H, Retegan M, Vlaicu R . Persistent complement activation on tumor cells in breast cancer. Am J Pathol. 1992; 140(5):1039-43. PMC: 1886512. View

16.

Bohana-Kashtan O, Ziporen L, Donin N, Kraus S, Fishelson Z . Cell signals transduced by complement. Mol Immunol. 2004; 41(6-7):583-97. DOI: 10.1016/j.molimm.2004.04.007. View

17.

Donninger H, Bonome T, Radonovich M, Pise-Masison C, Brady J, Shih J . Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene. 2004; 23(49):8065-77. DOI: 10.1038/sj.onc.1207959. View

18.

Fosbrink M, Niculescu F, Rus H . The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res. 2004; 31(1):37-46. DOI: 10.1385/IR:31:1:37. View

19.

Fosbrink M, Cudrici C, Niculescu F, Badea T, David S, Shamsuddin A . Overexpression of RGC-32 in colon cancer and other tumors. Exp Mol Pathol. 2005; 78(2):116-22. DOI: 10.1016/j.yexmp.2004.11.001. View

20.

Bjorge L, Hakulinen J, Vintermyr O, Jarva H, Jensen T, Iversen O . Ascitic complement system in ovarian cancer. Br J Cancer. 2005; 92(5):895-905. PMC: 2361909. DOI: 10.1038/sj.bjc.6602334. View